The isotope maker saw a slight increase in revenues in the third quarter to $67.1 million, up 0.5 per cent from $66.8 million in the same period last year.
In a statement, CEO Steve West said the company's TheraSphere cancer therapy business is driving much of the growth.
"Nordion delivered improved and solid performance across our businesses," stated Mr. West.
"We increased our margins and generated double-digit TheraSphere growth. Management continues to focus on building the business and improving alignment within each of our portfolios."
The revenues from that division, which amounted to a 15-per-cent year-over-year increase to $15 million, was mostly due to new clinic adoption, Nordion stated.
Historically, Nordion is a medical isotope maker, but has seen declines following some shutdowns at its main generation plant at Chalk River. This quarter, its medical isotope revenue fell eight per cent year-over-year to $19.7 million.
The reactor was shut down for one month between May and June and affected the company's supply of isotopes between the second and third quarters of this year, Nordion stated.
Although production has restarted, the company said it has fewer customers seeking the isotopes, partly because the clients are seeking to get multiple sources of supply.